Lipoprotein (a) and Vascular Regenerative Cell Content

Last updated: October 2, 2024
Sponsor: Canadian Medical and Surgical Knowledge Translation Research Group
Overall Status: Active - Recruiting

Phase

N/A

Condition

Dyslipidemia

Cardiovascular Disease

Circulation Disorders

Treatment

N/A

Clinical Study ID

NCT06626659
Pro00080565
  • Ages 18-80
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

Lp(a)-VRCE is an observational, cross sectional study looking at vessel reparative stem cell content in people with and without elevated lipoprotein (a) [Lp(a)]. Specifically, the type and number of these cells in peripheral blood samples will be measured in participants with Lp(a) ≥100 nmol/L and compared to participants with Lp(a) < 100 nmol/L. Determining the presence or absence of specific cells with blood vessel repair capacity in participants with high Lp(a) will further our knowledge of potential mechanisms through which Lp(a) influences cardiovascular health.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Adults ≥18 years of age and ≤80 years of age who meet either of the followingcriteria:

  2. Elevated Lp(a) (defined as greater than or equal to 100 nmol/L)

  3. Non-elevated Lp(a) (defined as less than 100 nmol/L)

  4. Willing and able to provide written informed consent and comply with studyprocedures.

Exclusion

Exclusion Criteria:

  1. Unable or unwilling to provide written informed consent or provide a peripheralblood sample.

  2. Any life-threatening disease expected to result in death within two years ofconsent.

  3. Any malignancy not considered cured (except basal cell carcinoma of the skin). Anindividual is considered cured if there has been no evidence of cancer recurrencefor the five years prior to screening.

  4. Uncontrolled hypertension.

  5. New York Heart Association Class IV heart failure.

  6. Active liver disease or liver dysfunction.

  7. Active kidney disease or kidney dysfunction.

  8. History of hemorrhagic stroke or other major bleeding disorder.

  9. White blood cell count ≥15 x 10^9/L.

  10. Women who are pregnant or nursing.

  11. Previously received ribonucleic acid therapy specifically targeting Lp(a).

  12. Active infectious disease requiring systemic antibiotic or anti-viral agents.

  13. Known acquired immunodeficiency syndrome, such as human immunodeficiency virus.

  14. On oral steroid therapy (e.g., prednisone or other corticosteroids) or otherimmunosuppressive agents (e.g., methotrexate).

  15. Treated autoimmune disorders.

  16. Participating in another study/trial that is likely to affect the primary outcome.

Study Design

Total Participants: 40
Study Start date:
October 01, 2024
Estimated Completion Date:
July 31, 2025

Study Description

Lipoprotein (a) [Lp(a)] is an independent, genetically determined, causal risk factor for the development of atherosclerotic cardiovascular disease. It is estimated that 20-30% of the global population have elevated Lp(a) and recent multinational guideline endorsements strongly advise the routine measuring of Lp(a), at least once in a person's life. Current Lp(a) risk level thresholds are described as <75 nmol/L for low risk and >125 nmol/L for high risk individuals. Despite ongoing clinical trials, there exists no approved therapeutic medication to specifically lower Lp(a).

Vascular regenerative cell exhaustion (VRCE) is described as the depletion of circulating pro-vascular reparative cells responsible for angiogenesis, vasculogenesis and arteriogenesis. Evidence in recent years has implicated VRCE as a novel mechanistic factor contributing to the aberrant cardiometabolic state present in type 2 diabetes, obesity, and in people of South Asian descent. It has been demonstrated that the VRCE phenotype can be reversed by treatment with sodium glucose co-transporter 2 inhibitors or bariatric surgery.

Lp(a)-VRCE is a cross-sectional, observational, two arm study enrolling 20 patients with elevated Lp(a) (≥100 nmol/L) and 20 patients with non-elevated Lp(a) (<100 nmol/L). From peripheral blood, mononuclear cells are isolated and enumerated via a multi-parametric flow cytometry assay utilizing aldehyde dehydrogenase activity and side scatter properties. The hypothesis is that people with elevated Lp(a) have comparatively different progenitor cell phenotypes to people with normal Lp(a) levels.

Connect with a study center

  • North York Diagnostic and Cardiac Centre

    North York, Ontario M6B1N6
    Canada

    Active - Recruiting

  • Diagnostic Assessment Centre

    Scarborough, Ontario M1S4N6
    Canada

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.